

Laurus Labs Limited  
Corporate Office  
2<sup>nd</sup> Floor, Serene Chambers, Road No. 7  
Banjara Hills, Hyderabad - 500034, Telangana, India  
T +91 40 6659 4333, 3980 4333, 2342 0500 / 501  
F +91 40 6659 4320 / 3980 4320



July 29, 2021

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	---

Dear Sirs,

Sub: Press Release

Please find enclosed the Press Release on the financial results for the quarter year ended June 30, 2021.

Please take the information on record.

Thanking you,

Yours sincerely,  
For **Laurus Labs Limited**

  
**G. Venkateswar Reddy**  
Company Secretary



Encl: As above

# Laurus Labs registers revenue growth of 31% and PAT Growth of 40%

Q1 FY22 Revenues up 31 %

Q1 FY22 EBITDA at ₹ 400 crs, up 41%, Margins at 31 %

Q1 FY22 PAT at ₹ 241 crs, up 40% Margins at 19 %

**Hyderabad, July 29, 2021:** Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven fully integrated pharmaceutical and biotech company in India announces its Q1 FY22 results.

## Q1 FY22 Laurus reported:

- Total net revenue ₹ 1,279 crs, up 31% (Y-o-Y)
- EBITDA ₹ 400 crs, up 41% (Y-o-Y)
- EBITDA margins at 31 %
- PAT at ₹ 241 Cr, up 40% (Y-o-Y)
- PAT margins at 19% (Y-o-Y)
- EPS (Diluted) for the period at ₹ 4.5 per share (not annualised), up by 40.6 % (Y-o-Y)

## Commenting on the results announcement, Dr. Satyanarayana Chava - CEO, said;

*"We have started the financial year 22 with strong growth in FDF, with the strong demand in ARV's for LMIC region and our portfolio expansion in developed markets. Our Synthesis business retained its growth momentum powered by the increased business from the existing clients and new clients; the segment registered strong growth with +95% YoY, with ongoing commercial supplies for four products. In the API segment, Oncology and ARV APIs registered healthy growth. In contrast, revenue from our other API witnessed a slowdown, and the growth is expected to restore from Q2 FY22, we remain confident of maintaining a growth trajectory in the Generic API business for FY22. In addition, Laurus Bio started contributing to the revenue and would add more from Q2 FY22, with the new fermentation capacities added in recombinant food protein."*

## Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said;

*"We are happy that Laurus Labs has registered revenue ₹ 1279 Crs in Q1 FY22, with 31% YoY. Our EBITDA margins were maintained at 31%. Laurus Bio has started contributing to revenues and margins from Q1 FY22. Our Gross Margins continue to grow on the back of a better product mix and improved sales from all the segments. Our performance focus is on growth driven by superior execution and completing our Future Ready strategy with manufacturing capacity expansions - a combination of brown and greenfield in API, FDF, and Synthesis divisions. With sustained business opportunities, we remain confident of achieving sustainable return ratios in the FY2022-23 and beyond."*

## Business Highlights:

### Overall

- Total Income at ₹ 1,279 Crs in Q1 FY22 growing by 31 % (Y-o-Y) Growth driven by sustained strong momentum across all business segments; particularly FDF and Synthesis
- R & D spent ₹ 49 Crs and 3.8 % of sales in Q1 FY22.

### Generic FDF

- Recorded sale of ₹ 521 Crs: 41 % contribution in FY 22 Q1
- Validation completed for 4 products apart from filling of 28 ANDAs & NDAs in total.
- Capacity expansion is in progress

### Generic API

- Filed 296 patents out of that 155 patents granted as of June 30, 2021
- Filed 66 DMFs
- Capacity expansion is in progress

### Synthesis

- Total Number of Active Projects in the CDMO division stood at 50 as of 30<sup>th</sup> June 2021.
- Commercial supplies ongoing for 4 products

*-ENDS-*

## About Us

Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs. We also develop and manufacture oral solid formulations, provide contract research and manufacturing services (CRAMS) to Global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals, in biotechnology we do animal origin free recombinant proteins.

We are passionate about advanced chemistry skills. Our proven expertise in bringing innovative solution, manufacturing efficiencies and unwavering quality focus has won us long-standing relationship with our global customers. Laurus employs 4800+ people, including around 750+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, UK-MHRA etc. and in FY2021 generated over Rs4,800 crore in annual revenue.

**Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

---

**Pavan Kumar N**  
**Laurus Labs Ltd.**  
Tel: +91 40 3980 4380  
Email: [mediarelations@lauruslabs.com](mailto:mediarelations@lauruslabs.com)



---

**DISCLAIMER:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.